Bayer AG has resolved a major legal dispute concerning its blockbuster ophthalmology treatment Aflibercept, paving the way for competing biosimilar versions to enter key global markets. The comprehensive agreement with rivals including Formycon establishes a clear timeline for the introduction of generic alternatives to one of the pharmaceutical giant’s most significant revenue drivers.
Legal Battles Concluded
The company had previously mounted an aggressive defense of its intellectual property. As recently as September 2025, Bayer secured a preliminary injunction against several generic drug manufacturers in the Munich Regional Court. This legal strategy relied on a specific formulation patent designed to extend market protection until June 2027, even though the basic substance patent had already expired. The new settlement with Regeneron, Bayer, and competitors Formycon and Klinge Biopharma ends all patent litigation surrounding copycat versions of the Aflibercept compound. This move eliminates litigation risks for the partners and clears the path for their upcoming product launches.
Market Launch Timeline Set
Under the terms of the accord, Bayer’s partners are permitted to begin marketing their biosimilars in Europe, Latin America, and the Asia-Pacific region starting in May 2026. The biosimilar products AHZANTIVE and Baiama have already received approval from the European Medicines Agency. A separate schedule is in place for the crucial United States market, where the launch of the Formycon alternative is slated for the fourth quarter of 2026.
Should investors sell immediately? Or is it worth buying Bayer PK?
Aflibercept is primarily used to treat severe retinal conditions such as wet age-related macular degeneration, where it works to prevent excessive blood vessel formation.
Mounting Pressure on Pharmaceuticals Division
The established entry dates for competing products intensify pressure on the revenue stream of Bayer’s pharmaceuticals unit. Company management had already identified the eye medicine segment as an area facing considerable headwinds from anticipated declining sales volumes. A parallel development is affecting the company’s blood thinner Xarelto, which is also confronting the expiration of key patents.
On the trading floor, Bayer shares showed stability at the week’s close. The stock closed at $11.07 USD. While this price sits approximately 11% below its 50-day moving average, it maintains a significant distance from its 52-week low of $5.35 USD. Forthcoming quarterly reports will reveal the extent to which the new competitive products influence the division’s long-term revenue forecast.
Ad
Bayer PK Stock: Buy or Sell?! New Bayer PK Analysis from March 21 delivers the answer:
The latest Bayer PK figures speak for themselves: Urgent action needed for Bayer PK investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from March 21.
Bayer PK: Buy or sell? Read more here...
